Any projections for Q1 sales out there?

[Anonymous]

Will the J-code or manuscript make any difference?

 

[Anonymous]

Will the J-code or manuscript make any difference?

No. There isnt a single account who had a problem with reimbursement for Folotyn with or without the J code. Manuscript does nothing. Do not assume physicians are unaware of ptcl or folotyn. They are very well informed and we have spent millions informing them of the drug. The issue remains the same. There are very few patients and those accounts with a patient or 2 cannot keep anyone on drug for more than 4-6 doses.

The 2011 nice price increase will be welcomed by my Top tier docs as well!

As for Q1 sales, just ask Paul about those. What is the number he gave Wall Street at the JP Morgan cocktail party? 15 Million? 18 million? Or was that the number of no cost options the board has given him? hmmm.

 

[Anonymous]

10 million. Not many happy with another price increase and as usual patients are few and far between. Dont believe the hype that docs are unaware of ptcl and folotyn. Weve spent millions hammering this message there just arent patient.

 

[Anonymous]

The projection is simple...we will all be out of work by Q3.

 

[Anonymous]

The projection is simple...we will all be out of work by Q3.

Yes. This is the unfortunate reality.